Outlook Therapeutics (Nasdaq: OTLK) releases financial results for FY 2025, focused on improving care for bevacizumab in retina diseases.
Iselin, New Jersey - On December 19, 2025, Outlook Therapeutics, Inc. disclosed their financial report for the fiscal year 2025. The biopharmaceutical company, listed as Nasdaq: OTLK, concentrates on improving the treatment standard of bevacizumab for retina diseases.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments